| Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities I Christodoulou, WJ Ho, A Marple, JW Ravich, A Tam, R Rahnama, ... Journal for immunotherapy of cancer 9 (12), 2021 | 67 | 2021 |
| Impact of high disease burden on survival in pediatric patients with B-ALL treated with tisagenlecleucel JW Ravich, S Huang, Y Zhou, P Brown, CH Pui, H Inaba, C Cheng, ... Transplantation and Cellular Therapy 28 (2), 73. e1-73. e9, 2022 | 24 | 2022 |
| Glycoprotein targeted CAR-NK cells for the treatment of SARS-CoV-2 infection I Christodoulou, R Rahnama, JW Ravich, J Seo, SN Zolov, AN Marple, ... Frontiers in immunology 12, 763460, 2021 | 19 | 2021 |
| Engineered interleukin-15 autocrine signaling invigorates anti-CD123 CAR-NK cells I Christodoulou, M Koldobskiy, WJ Ho, A Marple, WJ Ravich, R Rahnama, ... Blood 138, 2806, 2021 | 5 | 2021 |
| CD123-CAR NK Cells are Activated by and Kill Acute Myeloid Leukemia I Christodoulou, A Marple, W Ravich, C Bonifant MOLECULAR THERAPY 28 (4), 151-151, 2020 | 2 | 2020 |
| Return to play after rotator cuff tear in National Football League athletes HE Lapica, RJ Burgmeier, JW Ravich, MR Schurhoff, LA Vargas JSES International 7 (4), 581-585, 2023 | | 2023 |
| Enhancing Engineered T Cell Persistence Mechanisms JW Ravich Johns Hopkins University, 2022 | | 2022 |
| CAR-NK Cells Targeting Sars-Cov-2 Glycosites As COVID-19 Treatment I Christodoulou, R Rahnama, WJ Ravich, J Seo, S Zolov, A Marple, ... Blood 138, 2803, 2021 | | 2021 |
